The deal comes three days after novo nordisk raised the stakes in its push to outbid pfizer, saying tuesday it would offer to pay as much as $10 billion for metsera For up to $10 billion, prevailing over novo nordisk a/s in a tumultuous bidding war after us regulatory opposition thwarted the danish drugmakerβs rival. That was higher than its previous bid of up to $9 billion which sparked a lawsuit from pfizer.
πππ€π€ ππ π«ππππ OnlyFans | @missyozilla review (Leaks, Videos, Nudes)
The new proposal for the coveted obesity drug developer is more than double the size of pfizerβs original bid and ends a squabble with novo nordisk that had resulted in lawsuits.
Pfizer wins $10 billion bid for metsera, securing entry into the booming obesity drug market
Novo nordisk withdraws over us antitrust risks after a heated bidding war. Metsera initially agreed to be acquired by pfizer in september for $4.9 billion, with additional cvrs down the line 30, novo nordisk tried to pinch metsera with an $8.5 billion offer Pfizer sued novo to stop the deal, and the two companies made a series of counteroffers, upping the potential windfall for metsera to upwards of $10 billion.
The announcement of the deal signaled an end to the bidding war for metsera between pfizer and novo nordisk, the danish maker of ozempic and wegovy. Agreed to buy metsera inc
